Moderna Ranked #1 as One of the World's Most Influential Companies by TIME
Moderna has been ranked #1 on TIME's list of the world's most influential companies for 2026. The recognition highlights the company's innovation in mRNA technology and its commitment to delivering value to patients and society, supported by recent approvals of mixed vaccines and strategic international partnerships.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 23:10
- 🔍 Collected: May 20, 2026 at 14:31
- 🤖 AI Analyzed: May 20, 2026 at 14:34 (2 min after Collected)
【CAMBRIDGE, Mass., May 12, 2026】Moderna (NASDAQ: MRNA) announced today that it has been ranked #1 as one of the world's most influential companies of 2026 by TIME magazine. The company was recognized for its pioneering efforts in mRNA technology and its focus on delivering meaningful value to patients and society.
Stéphane Bancel, CEO of Moderna, said, "We are honored to be recognized by TIME as one of the most influential companies. This reflects our commitment to our mission and the dedication of our team to advancing mRNA science for patients. We will continue to develop innovative medicines for critical unmet medical needs, expand the reach of our platform across infectious diseases, cancer, and rare diseases, and strengthen pandemic preparedness for people and communities worldwide."
In 2026, Moderna obtained European approval for 'mCOMBRIAX®,' its fourth product, a mixed vaccine for influenza and COVID-19. Alongside the expansion of its product portfolio, the company continues to invest in long-term strategic partnerships with the UK, Canada, and Australia to support pandemic preparedness through increased manufacturing capacity and reduced response times.
Moderna also celebrated the fourth anniversary of the Moderna Charitable Foundation and released its fourth annual 'Impacting Human Health Report.' Through the mRNA Access program, the company has partnered with the scientific community, providing researchers access to its mRNA technology to explore new vaccines for emerging and neglected infectious diseases. Since its launch in 2022, this program has expanded to 35 research institutions worldwide.
The ranking, released by TIME and Statista, is based on scientific methodology using the 'Net Impact Model' from 'The Upright Project,' comprehensively evaluating contribution across social, knowledge, health, and environmental perspectives.
Stéphane Bancel, CEO of Moderna, said, "We are honored to be recognized by TIME as one of the most influential companies. This reflects our commitment to our mission and the dedication of our team to advancing mRNA science for patients. We will continue to develop innovative medicines for critical unmet medical needs, expand the reach of our platform across infectious diseases, cancer, and rare diseases, and strengthen pandemic preparedness for people and communities worldwide."
In 2026, Moderna obtained European approval for 'mCOMBRIAX®,' its fourth product, a mixed vaccine for influenza and COVID-19. Alongside the expansion of its product portfolio, the company continues to invest in long-term strategic partnerships with the UK, Canada, and Australia to support pandemic preparedness through increased manufacturing capacity and reduced response times.
Moderna also celebrated the fourth anniversary of the Moderna Charitable Foundation and released its fourth annual 'Impacting Human Health Report.' Through the mRNA Access program, the company has partnered with the scientific community, providing researchers access to its mRNA technology to explore new vaccines for emerging and neglected infectious diseases. Since its launch in 2022, this program has expanded to 35 research institutions worldwide.
The ranking, released by TIME and Statista, is based on scientific methodology using the 'Net Impact Model' from 'The Upright Project,' comprehensively evaluating contribution across social, knowledge, health, and environmental perspectives.
FAQ
Why was Moderna ranked #1 by TIME?
Moderna was recognized for its pioneering mRNA technology, innovative drug development for pandemic preparedness, and contribution to global health and society.
What is Moderna's main business?
Moderna develops mRNA-based vaccines and therapies for infectious diseases, cancer, and rare diseases.
What is the mRNA Access program?
It is a collaborative program providing researchers access to mRNA technology to explore new vaccines for emerging and neglected infectious diseases.